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Potential predictive biomarkers are often measured on a continuous scale, but in practice, a threshold value to
divide the patient population into biomarker ‘positive’ and ‘negative’ is desirable. Early phase clinical trials
are increasingly using biomarkers for patient selection, but at this stage, it is likely that little will be known about
the relationship between the biomarker and the treatment outcome. We describe a single-arm trial design with
adaptive enrichment, which can increase power to demonstrate efﬁcacy within a patient subpopulation, the pa-
rameters of which are also estimated. Our design enables us to learn about the biomarker and optimally adjust
the threshold during the study, using a combination of generalised linear modelling and Bayesian prediction. At
the ﬁnal analysis, a binomial exact test is carried out, allowing the hypothesis that ‘no population subset exists in
which the novel treatment has a desirable response rate’ to be tested. Through extensive simulations, we are able
to show increased power over ﬁxed threshold methods in many situations without increasing the type-I error
rate. We also show that estimates of the threshold, which deﬁnes the population subset, are unbiased and often
more precise than those from ﬁxed threshold studies. We provide an example of the method applied
(retrospectively) to publically available data from a study of the use of tamoxifen after mastectomy by the Ger-
man Breast Study Group, where progesterone receptor is the biomarker of interest. © 2016 The Authors. Statis-
tics in Medicine published by John Wiley & Sons Ltd.
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1. Introduction
The development of drugs is rapidly changing from the traditional pipeline in which all patients with a
broad phenotype are targeted by a single compound. It is now better understood that a broad phenotype
is often a collection of similar phenotypes, and that biomarkers may be used as direct or indirect indica-
tors of the subpopulation in which a particular drug is efﬁcacious. For example, olaparib, a treatment
which is effective in patients with BRCA-mutated breast cancer, does not appear to be effective in other
patients with breast cancer [1–3]. There has been very little research into how biomarker ‘positive’ and
‘negative’ groups should be deﬁned if the basic measure of a predictive biomarker is on a continuous
scale. During clinical trials of targeted treatments, it is of interest to determine as early as possible
whether there is a population/subpopulation in which the novel treatment is efﬁcacious and how this tar-
get group should be deﬁned. This might be aided by carrying out separate signiﬁcance tests in different
subpopulations and using these to inform the next phase [4,5] or by incorporating more efﬁcient decision
making through an adaptive design [6–8].
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Some published methods of clinical trial data analysis incorporate the classiﬁcation of a subset of patients
beneﬁtting from a treatment. For example, a Bayesian analysis which uses tree splitting based on factors in-
cluding potential predictive dichotomous biomarkers [9] has been suggested. Algorithmic methods, includ-
ing basic and cross-validated Adaptive Signature Designs [10,11], Virtual Twins [12] and SIDEScreen [13],
also aim to choose the most appropriate subpopulation based on a set of biomarkers. With these methods,
the biomarkers may be continuous and can be selected from a moderately large set of proposed factors.
There are also clinical trial designs which adaptively choose a subset during recruitment. The group
sequential design for subgroups [14] could be used when the total population is made up of disjoint sub-
sets. This may be appropriate when there is a single biomarker with a small number of levels or alterna-
tively a small number of biomarkers which can each be classiﬁed as positive or negative, with the
combined signature giving the subsets.
For a continuous biomarker, we deﬁne the true threshold or cut-off as the value which divides the
population into two subsets, such that the treatment is considered to be effective in one of these subsets,
and that this ‘positive’ subset is as large as possible. Ideally, these groups should be deﬁned from clinical
data, although frequently, the deﬁnition of these groups will be determined using separate data of ques-
tionable relevance, for example, from animal models. Even worse, the dividing threshold may simply be
based on a value which is considered convenient. The biomarker-adaptive threshold design [15] is an
algorithmic testing procedure which retrospectively aims to ﬁnd the appropriate cut-point. This requires
adjustments for multiple testing and could result in low power in an early phase clinical trial if a very
small number of subjects are recruited with biomarker values above that cutpoint.
Tests of effect size in the ‘positive’ subset will be higher powered if this subset is enriched, and Simon
and Simon [16] provide an adaptive enrichment solution. This study design assumes that there are two
distinct response rates, one common to participants on the novel treatment with biomarker values below
the true threshold and those on the control, and a higher one for those on the novel treatment with bio-
marker values above the threshold. An alternative adaptive design is suggested by Renfro et al. [17],
which uses a set of models ﬁtted across a reasonable range of cut-offs at the interim analysis. Depending
on the results of these models, recruitment either continues from the whole population, from a sub-
population based on the best identiﬁed cut-off, or the trial is stopped for futility. The ﬁnal tests for efﬁ-
cacy may also be based on either all recruited subjects or only those in the biomarker ‘positive’ subset,
dependent on the stage two recruitment strategy.
We suggest an alternative adaptive recruitment design, the continuous biomarker-adaptive threshold
trial (CBATT), which both selectively recruits from the start of the study and also updates the recruit-
ment threshold to target a study population, which will have a statistically signiﬁcant response rate. It
has the advantage over the Renfro method [17] that all subjects will be used in the ﬁnal test for efﬁcacy,
even if the recruitment strategy is changed at the interim. The basic study design contains a single arm,
which is typical of early phase II oncology trials, although it could be modiﬁed to include a control arm.
Recruitment is restricted using a preliminary threshold, and this recruitment threshold adapted following
an interim analysis. Our adaptive recruitment design is ideal for an early phase clinical study as it aims to
both demonstrate that there is a subpopulation in which the treatment is effective and estimate the most
appropriate value of the biomarker to deﬁne the boundary of this subpopulation. This allows later phase
studies to focus on this subpopulation alone.
In Section 2, we describe CBATT, stating a suitable interim analysis for a treatment with binary out-
come and describing the eligibility criteria based on the value of the biomarker. We show a hypothesis
test at the conclusion of the study and suggest a method for choosing an appropriate biomarker threshold
to partition biomarker ‘positive’ and ‘negative’ patients in future applications of the treatment. In
Section 3, we demonstrate the efﬁcacy of our design in a number of scenarios, through a simulation
study. In Section 4, we apply this design to data from the German Breast Study Group, investigating
the use of hormonal therapy (tamoxifen) after mastectomy [18,19]. The simulations and analysis were
carried out using R [20]. In Section 5, we discuss the potential of this design as well as its limitations
and suggest ways in which this method could be modiﬁed.
2. An adaptive threshold trial design
In this section, we describe a single-arm trial design for a treatment with a binary outcome: either re-
sponse or non-response. The objectives of the trial are to demonstrate the efﬁcacy of the drug and to
identify a subpopulation with a clinically relevant response rate. We assume a strong prior belief that
a single biomarker measured on a continuous scale predicts the response rate in a monotonic
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relationship, with higher biomarker values relating to higher response rates. If the association is believed
to be negative, the analyses should be adjusted appropriately.
Figure 1 shows a general overview of the study design, outlining the different stages and some of the
key methods that are employed. The design requires the sample size, signiﬁcance level and target power
to be ﬁxed at the beginning of the study. At the interim analysis, different possible recruitment thresh-
olds are proposed for the second stage, the power that would be achieved if these were used is predicted
and an updated recruitment threshold with a predicted power exceeding the target power chosen. If no
predicted powers achieve the target power, there are several options, including early stopping for futility.
Although we describe a two-stage study, this could be extended to include further interim analyses.
2.1. Overview of study design and notation
The primary aim of the study is to determine whether a subpopulation exists for which the response rate
exceeds a pre-deﬁned reference or ‘null’ response rate, ρ, justifying the progression of the drug in the
Figure 1. Flow diagram outlining the key steps in the continuous biomarker-adaptive threshold trial design,
which are described in detail in Sections 2.1 to 2.3 of the main text.
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clinical pipeline. The value of ρ should be chosen for clinical signiﬁcance, for example, equal to or
slightly higher than a historical response rate for a standard treatment. Part of the analysis involves in-
tegrating over the range of biomarker values (details in Supplementary material S1), and this is simpli-
ﬁed by converting the measure of the biomarker to its estimated quantiles across the subject population,
such that B~Unif[0,1]. The response rate at biomarker quantile B is written as π(B), and the response
rate in the subpopulation with biomarker quantile ≥B is written as Π(B). Where T* denotes a possible
biomarker quantile threshold value, the primary null and alternative hypotheses can be written
H0 : ∀ T : Π Tð Þ≤ρ;
HA : ∃ T : Π Tð Þ > ρ:
We carry out a binomial exact test using all the subjects recruited to the trial. Due to our assumptions,
this can be considered as a test at a single value of T*, and if the null hypothesis can be rejected at this
value, thenH0 can also be rejected. If this can be carried out, the secondary objective is to estimate the true
threshold quantile of the biomarker, T, which deﬁnes the lower bound of the subpopulation of interest.
An adaptive design with a single interim analysis is used. The total sample size, S, and the stage spe-
ciﬁc sample sizes, Si (S=S1 +S2), are ﬁxed before the study begins. In order to increase the estimation
accuracy of Π(B) at higher values of B using this ﬁxed S, only subjects with Bj≥ ti are recruited, where
Bj is the quantile value of the biomarker in subject j=1,…,S, and ti is the threshold in stage i. t1 should be
chosen based on prior knowledge (refer to Section 3.4), and t2 should be chosen to aim to achieve a par-
ticular power in the hypothesis test at the end of the study, based on the results from stage 1. The sig-
niﬁcance level and target power in the hypothesis test are written as α and 1-β, respectively.
For each subject, an indicator of response, xj = 0,1, is recorded. The overall and stage speciﬁc
numbers of responses are denoted Xob =Σj xj and Xob,i respectively. Because S, ρ and the signiﬁcance
level, α, are pre-speciﬁed, we can use the inverse of the binominal distribution function to calculate
XH, the minimum number of responses that would produce a signiﬁcant result, before the study
begins. After stage 1, the remainder required is XH,2 =XHXob,1. We also deﬁne RH=XH /S as the
required response rate for the study to be signiﬁcant and TH the biomarker quantile value such that
Π(TH=RH).
2.2. Interim analysis
After choosing suitable values of the design parameters for the study and carrying out the stage 1 recruit-
ment, an interim analysis with several steps is carried out.
As we assume that the response rate is monotonically increasing with increased levels of the bio-
marker, so that Π(max(t1,t2))≥Π(min(t1,t2)), we can use the binomial exact test P(X≥Xob |X~Bi(S,ρ))
to test the following hypotheses at the end of the study:
H0 : Π max t1; t2ð Þð Þ≤ρ;
HA : Π max t1; t2ð Þð Þ > ρ:
These hypotheses are not the same as H0 and HA, but if H0* is rejected, then H0 can also be rejected.
At the interim, we use Bayesian beta-binomial prediction models to calculate the probability of observ-
ing the remaining number of required responses, XH,2, in stage 2, based on what has been observed in
stage 1. This probability is calculated at different values of T* and is the predicted power, 1 β′T , of
a signiﬁcant hypothesis test result if t2 =T*. The values of T* from which t2 will be chosen are given
in the vector t2* and should be chosen by the clinical team such that they cover the full range of clini-
cally meaningful values of the biomarker. It should also be considered that any value in t2* could be cho-
sen as t2, so only recruitment thresholds that could be reasonably be used during stage 2 should be used
(for example, t2 = 0.99 would result in only 1% of the disease population are being recruited, which may
not be appropriate).
2.2.1. Modelling response rate for population subsets based on stage 1 data. So long as the relation-
ship between B and the probability of response can be assumed to be smooth and monotonic, it is rea-
sonable to model it using a logistic regression model, π(B) = exp(z) / (1 + exp(z)), with linear predictor
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z= δ0 + δ1B. A heavier tailed curve may be better modelled by a probit model, for example, but this de-
sign is not powered to choose between two types of model. Fitting the data from stage 1 to such a model
gives unbiased estimates of the response rates at ﬁxed values of B, including B< t1. However, Π(B), the
response rate in a population subset is more meaningful than π(B) in this trial design, and we show in
Supplementary material S1 how this function can be derived from the logistic model:
Π Bð Þ ¼ ln 1 þ exp δ0 þ δ1ð Þ
1þ exp δ0 þ δ1Bð Þ
 
=δ1 1 Bð Þ:
To account for the uncertainty in the maximum-likelihood estimates of the ﬁtted model coefﬁcients,
δ̂0; δ̂1ð Þ, and therefore in π ̂ Bð Þ and Π ̂ Bð Þ, we generate 1000 realisations of hypothetical model coefﬁ-
cients using the Fisher information matrix from the ﬁtted model:
δ̃0
δ1̃
 eMVN δˆ0
δˆ1
 
;
σ20 σ01
σ01 σ21
  
:
Each realisation of δ̃0; δ ̃1
 
gives an estimate of the biomarker subgroup model, Π ̃ Bð Þ , given
B~Unif[0,1].
2.2.2. Beta-binomial prediction. For each of the k potential threshold values in t2*, we can generate
1000 Π ̃ B ¼ t2;k
 
values using the different δ̃0; δ1̃
 
, which are estimates of Π t2;k
 
and take into ac-
count the uncertainty from the stage 1 data. To these values, we ﬁt a beta distribution
Π ̃ t2;k
 eB at2;k ; bt2;k  and predict the number of responses in stage 2 using X t2;keBBi S2; at2;k ; bt2;k .
We use these beta-binomial distributions to calculate the predicted power, 1 β′t2;k ¼ P X t2;k≥XH;2
 
.
The recruitment threshold for stage 2, t2, is the minimum t2;k such that 1 β′t2;k≥1 β.
Use of this beta distribution is convenient because it is a conjugate prior, is empirically based on the
stage 1 data and can easily accommodate different distributional assumptions of location and dispersion.
The latter is particularly appropriate when we want to update our probabilities. We investigated whether
the use of beta distributions is suitable by comparing it with using densities derived from Markov chain
Monte Carlo (MCMC) methods with various simulated datasets. We found that the beta density was
usually close to the MCMC density, and the two methods tended to give similar ﬁnal results. An exam-
ple illustration is given in Supplementary Figure 1. The MCMC method is more computationally inten-
sive but allows our method to be generalised where a logistic model and beta densities cannot be
assumed.
It may be the case that none of the values in t2 have the property 1 β′t2;k≥1 β, that is, no threshold
achieves the desired predicted power. This could be used as a strict stopping rule. When the largest t2;k,
t2;max, has an acceptably high 1 β′t2;max , it may be decided to progress with t2 = t2;k. Guidelines for the
application of such rules are given in Section 2.4.
2.3. Analyses after stage two
2.3.1. Signiﬁcance test for demonstrating efﬁcacy. If the trial is not stopped at the interim, S2 subjects
with Bj≥ t2 will be recruited and observed to see how many respond to the treatment. The binomial exact
test P(X≥Xob |X~Bi(S,ρ)) should produce a signiﬁcant result at level α with a probability of approxi-
mately 1 β′t2 , allowing for H0, and therefore also H0, to be rejected. This result supports proceeding
to the next stage of clinical development, but we also wish to be able to deﬁne the subpopulation in
which the drug should be tested.
2.3.2. Estimating the true threshold. The full dataset can be modelled in the same way that the stage 1
data were modelled at the interim analysis: ﬁtting a logistic regression model to π(B), generating 1000
realisations of the regression coefﬁcients of δ ̃0; δ1̃
 
and using these to calculate 1000 Π ̃ Bð Þ estimates
at each T*. If Πˆ Bð Þ is calculated in the same way using δˆ0; δˆ1
 
, the maximum-likelihood estimate of the
true threshold, Tˆ , is the value of B at which min Πˆ Bð Þ  ρ   occurs. The distribution of
A. V. SPENCER ET AL.
© 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 4909–4923
4913
min Π ̃ Bð Þ  ρ   can be used to ﬁnd values of B, which give conﬁdence intervals around Tˆ . In
Section 3.3, we show that Tˆ is an unbiased estimate of T.
2.4. Implementing either a ﬁxed or adaptive threshold design
The adaptive design is based around a target predictive power (1-β), and as discussed in Section 2.2.2,
there are several options for rules if there is no t2;k such that 1 β′t2;k≥1 β. Here, we suggest three ver-
sions of the adaptive design, one with a strict stopping rule at the interim, one with no stopping rule and
one which is a compromise between these. We also suggest two ﬁxed threshold designs, one with a stop-
ping rule and one without, which we use to compare to the adaptive methods in the simulations in
Section 3. Many studies include futility stopping rules at an interim analysis. An example of a
biomarker-based design which does this is SWOG S0819 [21], which includes rules to stop early for fu-
tility both in the EGFR FISH+ and non-positive groups. The paper by Redman et al. includes some dis-
cussion around the inclusion of futility monitoring for the subgroups deﬁned by the biomarker.
Adaptive design 1 (AD1) is the adaptive design which uses, in stage 2, the lowest threshold with a
predicted power greater than 1-β. If no such threshold exists, the study is stopped early at the interim.
Adaptive design 2 (AD2) is a variation on AD1. In AD2, if there is no threshold with predicted power
greater than 1-β, the maximum threshold (t2;max) will be used in stage 2, but only if the predicted power
at this threshold is greater than another predeﬁned value, γ. Otherwise, the study will be terminated. AD1
is a special case of AD2 with γ=1-β. Another special case is adaptive design 3 (AD3), where γ=0,
meaning, it has no minimum predicted power limit to using t2;max, so no trials stop early.
Fixed design 1 (FD1) uses a ﬁxed threshold throughout the study. However, an interim analysis is car-
ried out, which does not use the biomarker data, and the following stopping rule is used after stage 1:
stop if P(Xob≥XH |Xob,2 ~BBi(S2, Xob,1, S1Xob,1))<1-βFD. Fixed design 2 (FD2) does not stop trials
early.
3. Simulation study
To test our study design, we simulated data from a number of possible scenarios. Our full R [20] sim-
ulation code is provided in the Supplementary material Section S2. We compared the simulated study
outcomes that would result from using the designs described in the preceding texts.
3.1. Simulated data and analysis parameters
Data were simulated from a population in which the true underlying response rate can be described by a
logistic curve, with linear predictor z= δ0 + δ1B. We assumed that the biomarker distribution was well
characterised and can be represented by the quantile values, so that B~U[0,1], and chose values of δ0
and δ1 (the log odds ratio), which resulted in particular values of T or TH, the true threshold as described
in the preceding texts relating to the response rate ρ or RH respectively. For the various simulation sce-
narios, we varied: values for S1 and S2, the sample sizes in stages 1 and 2 and t1, the lower recruitment
threshold in stage 1. Other parameters were kept constant, with α=0.05, 1-β=0.8, and where there was a
true threshold, ρ=0.4. 5000 iterations were run using each particular set of values.
For each iteration, data for stage 1 were generated using Bi ~U[t1, 1];Xi ~Bern(π(Bi)). We allowed 20
possible values that t2 could take, t2 = (0, 0.05, 0.1, … , 0.95). The predicted power was calculated for
each of these values. Data were then generated for 20 possible stage 2 s, each using a different value
of t2. This allowed us, post-simulation, to consider which 5000 of the 20*5000 potential stage 2 s would
have occurred under different interim decisions, and how these choices affect power.
The main focus is the comparison of AD1 with 1-β=0.8 with FD1 with 1-βFD=0.2. The ﬁxed threshold
in FD1 is equivalent to t1 in AD1, so the stopping rules are in AD1, stop if p(success)<1 β = 0.8 ∀ t2,k,
and in FD1, stop if p(success)<1 βFD = 0.2 | t2 = t1. However, these probabilities of success are not cal-
culated in the same way, with the FD1 method using the observed values directly rather than the output of
logistic modelling and simulations.
3.2. Results of a basic adaptive study for simulation scenarios
3.2.1. Type-I error rate. The type-I error rate (TOER) can be examined by looking at the proportion of
signiﬁcant study results in scenarios where H0 is true. Using S1 =S2 = 50 and t1 =0.5, we analysed
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simulated data from a number of underlying logistic curves with Π(0.95) just under ρ=0.4, and the re-
sults of these simulations are give in Table I. The overall TOER is very low for both designs in all of
these scenarios and is usually slightly smaller when the adaptive design is employed. Although the
TOER in the completed studies is often higher when using the adaptive design, it should be taken into
account that this is a proportion of a much smaller number of the 5000 simulated studies reaching com-
pletion. For example, with Π(0) = 0.39, 91 of 454 completed studies had signiﬁcant results when using
the adaptive design compared with 143 of 1095 using the ﬁxed design. This highlights that the results
are affected by the different stopping rules applied in the two designs (refer to Sections 2.4 and 3.1).
The TOER is not speciﬁcally controlled at the chosen α value (0.05), but importantly, it is bounded at
this level and is conservative. This is because the number of responders needed to get a signiﬁcant re-
sponse (XH) is always 49, but the probability of observing this number increases with Π(0). Also, pre-
diction at the interim analysis causes the majority of studies to stop early, some of which would have
produced signiﬁcant results if they were to continue. These low TOERs suggest that higher values of
α could be implemented, whilst maintaining overall control of TOER, thus increasing the power of
the method.
The last two columns of Table I contain the ratio of participants that would have to be screened (as-
suming a representative distribution of the biomarker in the sample) in the adaptive design studies com-
pared with the ﬁxed designs in order to recruit the required sample size. By ‘screening’, we mean
measuring the biomarker value in otherwise suitable study participants to ﬁnd those with B> ti. Using
a ﬁxed design with S1 =S2 = 50, t1 = t2 = 0.5, the approximate number of subjects screened would be
100 for a study stopped at the interim and 200 for one which reaches completion. Taking into account
the completed studies only, the given ratio is >1 when the simulated adaptive studies usually have
t2>0.5 and increases with the average value of t2.
3.2.2. Non-null scenarios with a range of true thresholds. We next considered how the results of AD1
and FD1 with a single set of parameters might vary under different scenarios where there is a biomarker
effect and HA is true but kept most of the parameters the same as those in the null scenarios in the pre-
ceding texts. We considered three magnitudes of the biomarker effect: δ1 =3, δ1 = 6 and δ1 =9, and we
simulated from curves with these δ1 values, which also had particular true threshold (T) values or
hypothesis-testing thresholds (TH). In Table II, we summarise the curves using Π(B) at B=0 and 0.95.
To demonstrate the range of simulated scenarios investigated, we show the logistic curves and corre-
sponding Π(B) functions for those in Table II in Supplementary Figure 2. The outcomes are two mea-
sures of power, the stopping rate and a ratio of subjects screened. The overall power is the proportion
of the total 5000 iterations that resulted in a signiﬁcant outcome in the hypothesis test. The power for
the completed studies is the proportion of studies not stopped at the interim, which went on to give a
signiﬁcant result. The proportion of studies stopped early (stopping rate) increases with the true thresh-
old, as the number of responses in stage 1, Xob,1, will generally decrease. Also, the proportion of studies
stopped early at a particular value of T varies more (dependent on δ1) in AD1 than in FD1.
Table I. Results from 5000 simulation iterations using adaptive design 1 and ﬁxed design 1 with S1 = S2 = 50,
t1 = 0.5, ρ= 0.4 and α= 0.05 in scenarios where H0 is true, but the maximum Π only just fails to reach ρ. Here,
the proportion of signiﬁcant simulations is a type-I error rate.
Π(0) Proportion signiﬁcant/
type-I error rate (overall)
Proportion signiﬁcant/
type-I error rate
(completed studies)a
Stopping
rate
Ratio of subjects
screened (AD1
to FD1)
Adaptive
design 1
Fixed
design 1
Adaptive
design 1
Fixed
design 1
Adaptive
design 1
Fixed
design 1
Overall Completed
studies
0.39 0.018 0.029 0.198 0.131 0.908 0.781 0.94 1.27
0.38 0.015 0.026 0.186 0.124 0.919 0.791 0.94 1.33
0.36 0.006 0.012 0.108 0.078 0.941 0.843 0.97 1.54
0.34 0.004 0.005 0.068 0.044 0.947 0.877 0.99 1.61
0.29 0.001 0.001 0.032 0.024 0.975 0.950 1.04 2.33
0.16 0 0 0 0 0.994 0.999 1.04 4.02
aWithin the subset of studies not stopped at the interim, the proportion which resulted in a signiﬁcant hypothesis test
result.
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Both the overall power and the power for the completed studies are greater when using AD1 rather
than FD1 for all simulations with T>0.3. The power of the adaptive design is generally closer to 0.8
than that of the ﬁxed design. Where T<< t1, using t2 = t1 = 0.5 (as in the ﬁxed design) is likely to result
in a power >0.8, so the adaptive design will usually choose t2< t1. In fact, for the simulations with
T=0.2 and with δ1 = 3, 6 and 9, the median values of t2 in the adaptive design are 0.5, 0.4 and 0.3 re-
spectively. This allows the stage 2 data to generate a more informative biomarker response curve.
For a particular δ1, the powers given in the table generally increase as T decreases. For FD1, this is
expected, because a lower T means that recruiting subjects with B> t1 = 0.5 will result in an overall
higher response rate. For AD1, the interim rule is to only continue the study using t2 if the predicted
power for this t2 is ≥0.8. This would suggest that the power in the completed studies should consistently
be slightly higher than 0.8. We observe cases where the power is much higher than 0.8, and this occurs
when T<< t1, as in this situation, sometimes even the smallest t2;k has predicted power >>0.8. How-
ever, we also see that when T is high and/or δ1 is low, the power in the completed studies can be much
lower than 0.8. This can be explained in terms of asymmetric decisions being made between underesti-
mates and overestimates of power for different t2;k and is discussed further in Section 5.2.
3.2.3. Scenarios in which the biomarker is not predictive. It may be the case that the biomarker is not
predictive of treatment response, and subjects with all values of B have the same probability of response
(Π). Table III contains the results for scenarios in which some subjects respond, but there is no bio-
marker effect. In some cases Π> ρ, so HA is true, but δ1 = 0 and T=0. The approximate number of
Table II. Results from 5000 simulation iterations using adaptive design 1 and ﬁxed design 1 with
S1 = S2 = 50, t1 = 0.5, ρ= 0.4, α= 0.05 and RH=XH / S= 0.49 in scenarios with a biomarker effect and where
HA is true. Here, the proportion of signiﬁcant simulations is power.
δ1 T
s.t.
Π
(T) = ρ
TH
s.t.
Π
(TH) =RH
Π(0) Π(0.95) Proportion
signiﬁcant/
power (overall)
Proportion
signiﬁcant/
power
(completed
studies)a
Stopping
rate
Ratio of
subjects screened
(AD1 to FD1)
Adaptive
design 1
Fixed
design 1
Adaptive
design 1
Fixed
design 1
Adaptive
design 1
Fixed
design 1
Overall Completed
studies
3 0.8 n/a 0.20 0.46 0.002 <0.001 0.067 0.024 0.967 0.984 1.16 3.21
6 0.8 0.93 0.13 0.51 0.002 0 0.069 0 0.974 >0.999 1.18 3.99
9 0.8 0.89 0.11 0.56 0.002 0 0.044 n/ab 0.964 1b 1.28 4.38b
3 0.6 0.85 0.24 0.53 0.036 0.008 0.273 0.069 0.866 0.890 1.36 2.42
6 0.6 0.74 0.19 0.65 0.148 0.001 0.503 0.020 0.706 0.941 2.24 2.83
9 0.6 0.71 0.17 0.74 0.350 0.001 0.717 0.014 0.512 0.958 3.14 2.83
3 0.5 0.76 0.27 0.56 0.110 0.037 0.448 0.153 0.755 0.760 1.49 2.22
6 0.5 0.65 0.22 0.71 0.384 0.033 0.729 0.144 0.474 0.771 2.28 2.21
9 0.5 0.62 0.21 0.81 0.669 0.039 0.831 0.161 0.195 0.755 2.80 2.04
3 0.4 0.66 0.29 0.60 0.228 0.145 0.570 0.340 0.600 0.573 1.41 1.76
6 0.4 0.56 0.26 0.76 0.623 0.237 0.795 0.447 0.217 0.469 1.85 1.67
9 0.4 0.53 0.24 0.86 0.827 0.336 0.866 0.562 0.046 0.402 1.74 1.43
3 0.23 0.5 0.34 0.66 0.477 0.510 0.734 0.699 0.350 0.271 1.20 1.33
6 0.33 0.5 0.28 0.79 0.732 0.522 0.824 0.704 0.111 0.259 1.45 1.35
9 0.35 0.5 0.26 0.89 0.844 0.599 0.856 0.766 0.014 0.218 1.33 1.20
3 0.2 0.48 0.35 0.66 0.515 0.586 0.750 0.758 0.314 0.227 1.17 1.28
6 0.2 0.38 0.33 0.84 0.830 0.913 0.847 0.968 0.020 0.057 1.03 1.01
9 0.2 0.36 0.32 0.93 0.859 0.983 0.860 0.996 0.001 0.013 0.88 0.88
3 0.02 0.3 0.397 0.72 0.872 0.599 0.880 0.766 0.112 0.218 1.04 1.20
6 0.10 0.3 0.36 0.87 0.895 0.990 0.899 0.997 0.005 0.007 0.85 0.85
9 0.13 0.3 0.35 0.95 0.901 0.997 0.901 >0.999 0 0.002 0.81 0.81
aWithin the subset of studies not stopped at the interim, the proportion which resulted in a signiﬁcant hypothesis test
result.
bIn this set of simulations, all studies with the ﬁxed threshold design were stopped at the interim so there are no com-
pleted studies; however, the ratio of screened subjects is calculated based on any theoretical ﬁxed design study that
was not stopped having screened 200 subjects.
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subjects that would need to be screened in any of these cases is fairly similar no matter which of the two
designs is used. However, as the response rate increases, the proportion of studies producing signiﬁcant
results (overall and amongst completed studies) increases for both study designs. The proportion of sig-
niﬁcant studies is very low when H0 is true (Π< ρ) and very high when Π>>ρ. In fact, when Π=0.35,
almost all studies are stopped at the interim (0.934 for the ﬁxed design and 0.975 for the adaptive de-
sign), whereas when Π=0.65, very few are stopped (0.001 and 0.018 respectively). Only in the cases
where Π>RH=0.49 do we see signiﬁcant proportions in the completed studies of 0.8 or higher.
For this subset of scenarios, it is possible to calculate the stopping rate and the probability of signif-
icance exactly. In Supplementary material S3, we demonstrate how these compare closely to the results
from the simulation.
3.3. Estimating T
The secondary aim of the adaptive study design is to estimate T, which can be carried out even if the
result of the hypothesis test is non-signiﬁcant. In each simulation, we found the bias in the estimate using
bias ¼ Tˆ T and summarised the uncertainty in Tˆ using conﬁdence intervals (CIs) based on the 1000
Π ̃ Tð Þ estimates in that study. We consider the median bias in each set of 5000 simulation iterations, as
well as the interquartile range of the estimates. For studies that did not reach completion, we used the
estimates from the logistic regression ﬁtted at the interim analysis.
Across all simulations, the average bias was very close to 0. For example, for the scenarios shown in
Table II, the median bias in Tˆ from the adaptive design analyses was always in the range (0.01, 0.03),
which is very similar to the equivalent range from using the ﬁxed design of (0.01, 0.02). The interquar-
tile range of Tˆgenerally increases slightly as the value of t1 increases, as less of the biomarker’s dynamic
range was studied in stage 1, but in most cases, this distribution was similar no matter whether AD1 or
FD1 was used. The exception to this is when t1 (the stage 1 threshold in AD1 or ﬁxed threshold in FD1)
is very close to 1, particularly if T is not. This can be observed by simulating a single scenario in which
T=0.6, δ1 =6, S1 =S2 =50, ρ=0.4, α=0.05 and a range of different values for t1. Boxplots of the bias in Tˆ
observed in these simulations are given in Figure 2. These show that for larger initial thresholds, the in-
terquartile range for Tˆwas generally smaller in AD1 than in FD1, for example, 0.17 compared with 0.20
when using t1 =0.8 and 0.19 compared with 0.74 when using t1 =0.9. Only a small proportion of studies
were stopped in these simulations, so these estimates mostly rely on completed studies; the main differ-
ence being that in AD1, the majority of studies had t2< t1. Fixing t at a very high value (as in FD1)
means that the estimates based on an extrapolated ﬁtted model will often be very poor. The estimates
are improved if some data come from lower values, for example, where t1 = 0.9, the median t2 in AD1
was 0.75 (other quartiles: 0.50, 0.85). The uncertainty in the individual study estimates of Tˆ is similarly
affected in these examples. The median width of the 50% CI in the simulations with t1 = 0.8 is 0.18 using
the ﬁxed design, 0.13 using the adaptive design and 0.33 and 0.14 respectively when t1 = 0.9.
Table III. Results from 5000 simulation iterations using adaptive design 1 and ﬁxed design 1 with S1 =S2 = 50,
t1 = 0.5, ρ=0.4 and α=0.05 in scenarios with no biomarker effect and therefore a constant response rate.
Π Proportion
signiﬁcant (overall)
Proportion signiﬁcant
(completed studies)a
Stopping rate Ratio of subjects
screened
(AD1 to FD1)
Adaptive
design 1
Fixed
design 1
Adaptive
design 1
Fixed
design 1
Adaptive
design 1
Fixed
design 1
Overall Completed
studies
0.35 <0.001 0.001 0.016 0.018 0.975 0.934 0.99 1.56
0.40 0.022 0.033 0.210 0.135 0.897 0.758 0.93 1.23
0.42 0.049 0.078 0.343 0.226 0.857 0.668 0.89 1.16
0.50 0.409 0.569 0.843 0.760 0.515 0.251 0.81 0.94
0.55 0.729 0.872 0.971 0.938 0.249 0.071 0.79 0.84
0.65 0.982 0.998 1 >0.999 0.018 0.001 0.76 0.76
aWithin the subset of studies not stopped at the interim, the proportion which resulted in a signiﬁcant hypothesis test
result.
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3.4. Choice of S and t1
For deployment of the method in any particular scenario, we recommend the use of simulations to under-
stand the power and operating characteristics of any proposed design and sample size. In order to aid
practitioners, we have included our R [20] simulation code in Supplementary material S2 for this purpose.
Power increases with t1 (Supplementary Figure 3b), but so does the uncertainty in Tˆ, meaning that there
is a trade-off when choosing this value. Time restrictions on the study also introduce a trade-off between S
and t1, as recruitment will not be from the whole population, and accrual rates in each stage depend on ti.
If TH can be estimated with some conﬁdence prior to the study, then we would suggest a value close to this
for t1, if it provides an acceptable screening rate. Supplementary material S4 examines the effect of chang-
ing the timing of the interim analysis. It appears that in general, using S2 =S1 will at least give close to the
highest possible power or the desired power (1-β) in the case t1>>T, although if a low value of t1 is be-
ing used for some reason, it may be advantageous to place the interim early in the study.
3.5. Using alternative study designs
In Section 2.4, we describe some alternative study designs implementing the same basic methods. These
alternatives might allow more studies to reach completion, and in particular, more studies in populations
where a subpopulation of interest does in fact exist (increasing the true positive rate). To investigate the
extent of this effect, we also applied adaptive AD2 and AD3 and FD2 to the simulated datasets. With the
adaptive designs, we continued to use 1-β=0.8, and with AD2, we set the minimum predicted power
with which a trial would be allowed to continue, γ, at 0.5.
Figure 3 displays the observed powers for 5000 iterations of ﬁve simulated scenarios, each analysed
using the ﬁve different study designs. In Figure 3a, we see the overall powers, and in Figure 3b, we see
Figure 2. The bias in 5000 iterations of a simulated study dependent on the stage 1 threshold (t1) and the study
design where AD1 is adaptive design 1 and FD1 is ﬁxed design 1. The data are generated from a logistic model
with T= 0.6 and δ1 = 6. Other parameters are ﬁxed at α= 0.05, 1-β = 0.8, ρ= 0.4 and S1 = S2 = 50.
Figure 3. The power of different study designs using t1 = 0.5, α= 0.05 and 1-β = 0.8 or 1-βFD = 0.2, ρ=0.4 and
S1 = S2 = 50, with δ1 = 6, but a variety of true thresholds. We give (a) the overall power (proportion of 5000 sim-
ulation iterations which have signiﬁcant hypothesis test results) and (b) the power within completed studies
(those iterations which are not stopped at the interim).
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the powers within the completed studies. Notice that the same results are given for AD3 and FD2 in both
ﬁgures, as these designs do not have stopping rules. As we previously observed for AD1 and FD1, all of
the adaptive designs generally have power closer to 0.8 than the ﬁxed designs. Allowing more studies to
reach completion increases the overall number that produce signiﬁcant results, so we see that in Figure 3
a, power(AD3)>power(AD2)>power(AD1) for all values of T. It is somewhat surprising, though, that
this is also the case at the lower values of T when we adjust for stopping at the interim. We would expect
the designs which stop fewer studies to have, on average, lower predicted powers and therefore also
lower observed powers. This is explained by the imbalance between over-prediction and under-
prediction of power (refer to Section 5.2), which will have the largest effect in AD1 (where predicted
powers need to be highest for the study to continue), and the fact that at these lower values of T, the tar-
get predicted power of 0.8 is likely to have only just been missed in a large proportion of studies (in
some cases due to under-prediction).
The results in Figure 3 might at ﬁrst seem to argue against using strict stopping rules, but such rules
allow early detection and stopping for futility when the null hypothesis is true. Take, for example, sim-
ulations of three scenarios with H0 true (Π(0) =0.36, Π(0.95) just below 0.4) and using t1 = 0.5, 0.7 and
0.9; the rest of the parameters are the same as those simulations in Figure 3. All three designs consis-
tently resulted in overall type-I error rates <0.04 and completed study TOERs <0.12, but whereas
AD3 would automatically take all studies to completion, AD2 stopped 77–84% of the studies, and
AD1 stopped 84–95% of the studies at the interim. In practice, these design parameters can be adjusted
to achieve an appropriate trade-off between false-positive and false-negative risks for the scenario under
which the study is being performed.
4. Case study
4.1. Data
To illustrate our method, we applied it retrospectively to the data from the German Breast Study Group
[18,19]. This dataset contains recurrence free survival (RFS) information on 686 patients with breast
cancer who had undergone a mastectomy, but we focus only on those given tamoxifen, a hormonal treat-
ment (n=246). The dataset includes baseline progesterone receptor (PR) measurement for all subjects.
In the original analysis, the continuous values were not used,but were instead split into positive or neg-
ative, with positive classed as PR ≥20 fmol/mg. We wished to investigate whether there is a subpopula-
tion with 65% RFS at 1500days after mastectomy which can be predicted by PR. For this retrospective
analysis, we therefore deﬁne a responder as a subject who is recurrence free after 1500 days and a non-
responder as a subject for whom recurrence or death occurred within 1500days. We realise that such a
long-term outcome is not typical of an adaptive design study where an earlier endpoint is required, but
this dataset is used to provide an illustration of the principle of the method. A number of subjects were
lost to follow-up within 1500days, so their data had to be discarded, leaving a total of 176 subjects in the
tamoxifen group.
We used the full set of 686 PR values to estimate the biomarker distribution across the patient popu-
lation and transform these to B~Unif[0,1]. As well as ρ=0.65, we set the initial study parameters at
S1 =S2 = 35, t1 =0.35 (which is equivalent to subjects with PR≥15 fmol/mg), α=0.05, 1-β=0.8. In order
to imitate the conditions of an ongoing study as closely as possible, we ‘recruited’ subjects by ascending
ID numbers. Our ‘adaptive design study’ therefore included the ﬁrst 35 subjects with PR ≥15 fmol/mg
and the subsequent 35 subjects based on t2, which was determined at the interim analysis.
4.2. Results
XH=53/70 responders (subjects who are recurrence free at 1500days) needed to be observed in order to
achieve a signiﬁcant test result, with the alternative hypothesis RR >0.65. In stage 1, we observed
Xob,1 = 26/35 responders, meaning that in stage 2, the target was XH,2 = 27. We ﬁtted a logistic regression
model and used the parameter estimates and covariance matrix to ﬁt beta distributions around Πˆ Tð Þ,
where t2 = (0, 0.05, 0.1, … , 0.95). Using the beta-binomial predictions at each of these potential thresh-
olds, the minimum t2;k with predicted P(Xob,2≥27)≥0.8 was 0.55.
After completing the ‘recruitment’ using t2 = 0.55 (equivalent to PR≥47 fmol/mg), there were exactly
27 further responders, meaning that the binomial exact test on the 70 selected subjects indicated that
there is a subgroup with 65% RFS in the tamoxifen-taking population (p=0.037). This subgroup is
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deﬁned by higher progesterone receptor counts, and using the Π(B) function, we can estimate that the
relevant threshold in terms of B, the progesterone receptor quantiles, is 0.2 (75% CI= (0, 0.35)). This
is equivalent to 4 fmol/mg (75% CI= (0, 15)).
Table IV compares the results of this retrospective CBATT study to those of an alternative retrospec-
tive subgroup analysis where the ﬁrst S=70 subjects with B> t=0.35 are ‘recruited’ (=t1 in the adaptive
design). In this case, a ﬁxed recruitment threshold of 0.35 resulted in 48 responders (p=0.312). The best
estimate of the true threshold value we are able to obtain comes from analysing the data of all subjects on
hormonal therapy whose survival data were not censored before 1500days. The point estimate is
11 fmol/mg, and this is within the 75% CIs of the estimates from both of the smaller subsets. The ﬁtted
Π(B) curves from both retrospective analyses and the full data analysis are shown in Figure 4.
5. Discussion
5.1. CBATT design and implementation
We have described an adaptive study design for single-armed clinical trials in which there is a poten-
tially predictive biomarker measured on a continuous scale which does not have a pre-deﬁned cut-off
for ‘biomarker positive’ subjects. Deﬁning the ‘true threshold’ as the biomarker value in the preceding
texts in which the subjects have the desired response rate, our design recruits subjects from a subset of
the population using an initial biomarker threshold. This recruitment threshold is adapted at an interim
analysis in order to optimise the information obtained about the biomarker response relationship whilst
also ensuring the desired level of power in the study. The interim analysis has been developed using
Table IV. Results of hypothesis tests (HA: RR> 0.65) on subsets (S= 70) of subjects on hormonal therapy
from the German Breast Study Group.
Recruitment Responders/total
sample size
Hypothesis
test p-value
Threshold estimate
(75% CI) fmol/mg
Adaptive threshold (CBATT with t1 = 0.35) 53 / 70 0.037 4 (0, 15)
Fixed threshold (t= 0.35) 48 / 70 0.312 8 (1, 20)
Full available data 96 / 176 n/a 11 (3, 32)
The subsets were ‘recruited’ with either the CBATT or ﬁxed threshold design. Final threshold estimates and 75% con-
ﬁdence intervals from these subsets are also included, as well as for the full 176 subjects in the dataset who were on
hormonal therapy and whose survival data were not censored before 1500 days.
Figure 4. Estimated average recurrence free survival rate at 1500 days after mastectomy for the subpopulation,
with progesterone receptor levels above those given on the x-axis. This was calculated with the full available data
(S=176) as well as with two ‘retrospective recruitment’ studies with S=70, ρ= 0.65, α= 0.05, 1-β = 0.8 and t1 or
t= 0.35.
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Bayesian beta-binomial prediction models, which predict that the power of binomial exact tests for re-
sponse rate at the study conclusion using different thresholds that may be used in stage 2.
The primary focus of the design is around testing for efﬁcacy in a subpopulation deﬁned by biomarker
values. In order to justify further development of a drug in more expensive later phase trials, robust dem-
onstration of a drug’s efﬁcacy is required. Once the efﬁcacy of the drug has been established, detailed un-
derstanding of factors, such as the patient population in which that drug is most effective will increase the
probability of successful development. Our method also allows for unbiased estimation of the biomarker-
response curve, and we would advocate the presentation of such results alongside hypothesis test results.
For ease of presentation, the method we have demonstrated uses a mixture of Bayesian and frequentist
methodologies. However, it would be relatively simple to work in a completely Bayesian framework,
using Bayesian logistic regression modelling and Bayesian hypothesis testing approaches.
Over a range of simulations with different true thresholds, the adaptive design with a stopping rule
(AD1) consistently outperformed a ﬁxed design with a stopping rule (FD1). We also demonstrated other
versions of the adaptive design (AD2 and AD3), which provide higher power still at the cost of an in-
creased probability of proceeding to study conclusion when the null hypothesis is true. Generally, in
simulations, the adaptive designs resulted in a power closer to the predicted power than ﬁxed designs
both with (FD1) and without (FD2) a stopping rule when the true threshold >0. These designs also pro-
duced similar power in simulated scenarios for which the reference response rate was observed overall,
but the biomarker was not predictive, and they had comparable type-I error rates. At the end of the study,
the true threshold can be estimated, and using an adaptive design results in an unbiased estimate. In sit-
uations when the initial recruitment threshold is greater than the true threshold, it also gives less uncer-
tainty in the ﬁnal threshold estimate than a ﬁxed design.
For the method to be effective, the approximate distribution of the biomarker in the subject population
must be known. This is because it is necessary to transform the biomarker measure to B~Unif[0,1], such
that Π(B) is the mean of π(B) in the range (B,1). We are primarily interested in this mean (or overall)
response rate in the subpopulation, even though if a threshold of T is chosen, some subjects with bio-
marker quantile (B) values >T will have π(B) below Π(T). In general, these response rates are high
enough that these subjects will still gain clinical beneﬁt from the treatment, but this may not be the case
if the logistic biomarker-response curve happens to be very steep, or if there are large gaps between the
proposed threshold values. We strongly recommend studying both the π(B) and Π(B) curves carefully
before choosing a threshold at the end of the study.
The choice of operating parameters in any particular scenario will depend on the circumstances and
objective of that individual study, although we can offer some general guidelines, and many of these
can be investigated further using the R [20] simulation code provided in the Supplementary material
Section S2. The reference response rate should be based on clinical signiﬁcance and a stage 1 threshold
chosen to be close to the best prior estimate of TH, the smallest value of B at which the response rate
would give a signiﬁcant hypothesis test result. The size of the study should be set considering the power
this would provide over a range of probable scenarios which can be estimated through simulation, and it
is recommended to use equal stage 1 and stage 2 sample sizes (Section 3.4 and Supplementary material
Section S4). It is important to take into account the potential number of participants that may have to be
screened as a result of changing the threshold in the adaptive recruitment.
We proposed alternative implementations of the adaptive design, all with a main target power (1-β)
and, upon failing to reach this target, each of which either stops at the interim or moves to the maximum
threshold if it has predicted power ≥γ. The adaptive designs explored through simulation in Section 3 all
used 1-β=0.8, and AD2 and AD3 always had γ=0.5 and γ=0 respectively. Different values for 1-β and
γ than those given here could be used, and the different costs of continuing to stage 2 in a null scenario,
false positive and true negative outcomes need to be weighed against each other when deciding on the
study design.
5.2. Observing powers well below the speciﬁed target power
The key components of our methodology are the speciﬁcation of a target power, 1-β, and the choice of a
stage 2 threshold based on achieving that power. However, in our simulations, we found that even when
a target power of 1-β was predicted, we may in fact observe a much lower power. We attempt to explain
this now.
Consider that at the interim, for each t2;k , there is a true binomial probability of observing at least
XH,2 =XHXob,1 responses in stage 2. This probability is unknown, so it is estimated using the stage
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1 data and the beta-binomial distribution. Consider that t2;k is the threshold which actually has binomial
probability just >0.8, so it is the ‘ideal’ choice for t2. This probability could be underestimated or
overestimated by the beta-binomial prediction. If it is overestimated, the study will deﬁnitely continue
to stage 2, either using t2;k or a smaller value in t

2, with predicted power also >0.8 (which must also
be an overestimate). If it is underestimated, then a larger value in t2 will be sought, which has predicted
power >0.8. In some cases, no such value will exist, meaning, the study will be terminated. Therefore,
more studies will reach completion in which the predicted power was an overestimate of the true bino-
mial probability than an underestimate. For a ﬁxed t1, this effect becomes more extreme when T is larger,
as Xob,1 is likely to be smaller, and therefore XH,2 is larger. The only way to not include a stopping rule is
to use a design like AD3, where the study continues at a threshold with a predicted power <1-β, and this
also results in observed power <1-β.
5.3. Extensions to the CBATT design
There are several ways of extending the methodology presented here. One would be to use multiple in-
terim analyses, which would improve the results if a poor choice for t1 had been made. If very little was
known prior to the study to inform the parameter choices, for example, this could be implemented
through an early interim with no stopping and then another half way through the remaining samples.
This could be extended to more analyses still, even continuous updating, but further simulations would
be required to evaluate how much value an approach such as this adds.
A way to decrease the number of studies stopped at the interim would be not to ﬁx S2 in advance. In a
study of this design, several potential sample sizes for stage 2, S2*, would have to be considered, and the
powers for different combinations of (t2*, S2*) would be compared. Choosing the optimum combination
of (t2*, S2*) would require a trade-off optimisation between multiple parameters, including power, study
cost and duration and the accuracy of the ﬁnal estimate of the threshold.
The design could be adapted to different types of outcome, such as continuous (e.g. tumour shrinkage
or a pharmacodynamic measurement) or time-to-event (e.g. number of days from baseline until either
disease progression occurs or follow-up is discontinued). The use of beta-binomial prediction is limited
to binomial outcomes and is simpliﬁed through the application of the convenient conjugate-prior model.
For a normally distributed outcome, conjugate-prior normal and gamma distributions could be used for
the mean and variance parameters. For an outcome where a conjugate-prior model is not available,
MCMC methods could be used to carry out the interim analysis and different appropriate models applied
to these data types.
A control arm could be included in the study design with little adaptation of the method, enabling com-
parison in a subgroup between the novel treatment and a placebo or standard of care. Initial investigation
of such a method has shown feasibility, but gains in power are limited due to the increased uncertainty
from estimating the biomarker response curve in both the experimental arm and also the control arm.
Several other variations on the design could be adopted to address the exact aims of a speciﬁc trial.
For example, including analysis of co-primary endpoints or treating stage 2 as an independent study.
5.4. Conclusions
We have presented a methodology for early-phase clinical trials which allows for ﬂexibility when a pre-
dictive biomarker is hypothesised but a priori cannot be used to separate subjects into ‘positive’ and
‘negative’ subsets with conﬁdence. This design includes a test for treatment efﬁcacy in a subset of the
population as well as estimation of the biomarker threshold deﬁning ‘positive’ subjects. Hence, the con-
tinuous biomarker-adaptive threshold trial efﬁciently combines two objectives which may otherwise be
investigated separately, increasing power over alternative methods.
Acknowledgements
AM and JW were supported by the Medical Research Council (grant number G0800860).The authors wish to
thank James Matcham and Amir Handzel for their support.
References
1. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ,
Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors
from BRCA mutation carriers. New England Journal of Medicine 2009; 361(2):123–134.
A. V. SPENCER ET AL.
© 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 4909–4923
4922
2. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer
SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in pa-
tients with advanced cancer and a germline BRCA1/2 mutation. Journal of Clinical Oncology 2015; 33(3):244–250.
3. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK,
Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in pa-
tients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet 2010; 376
(9737):235–244.
4. Wang SJ, O’Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic
subset. Pharmaceutical Statistics 2007; 6(3):227–244.
5. Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials.
Statistics in Medicine 2012; 31(30):4309–4320.
6. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection
using correlated survival endpoints. Pharmaceutical Statistics 2011; 10(4):347–356.
7. Jones CL, Holmgren E. An adaptive Simon two-stage design for phase 2 studies of targeted therapies. Contemporary Clin-
ical Trials 2007; 28(5):654–661.
8. Rosenblum M, Van der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations beneﬁt from
treatment. Biometrika 2011; 98(4):845–860.
9. Berger JO, Wang X, Shen L. A Bayesian approach to subgroup identiﬁcation. Journal of Biopharmaceutical Statistics
2014; 24(1):110–129.
10. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a
gene expression signature for sensitive patients. Clinical Cancer Research 2005; 11(21):7872–7878.
11. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clinical Cancer Research 2010; 16
(2):691–698.
12. Foster JC, Taylor JM, Ruberg SJ. Subgroup identiﬁcation from randomized clinical trial data. Statistics in Medicine 2011;
30(24):2867–2880.
13. Lipkovich I, Dmitrienko A. Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect
in clinical trials using SIDES. Journal of Biopharmaceutical Statistics 2014; 24(1):130–153.
14. Magnusson BP, Turnbull BW. Group sequential enrichment design incorporating subgroup selection. Statistics in Medi-
cine 2013; 32(16):2695–2714.
15. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible
biomarker-deﬁned subset effect. Journal of the National Cancer Institute 2007; 99(13):1036–1043.
16. Simon N, Simon R. Adaptive enrichment designs for clinical trials. Biostatistics 2013; 14(4):613–625.
17. Renfro LA, Coughlin CM, Grothey AM, Sargent DJ. Adaptive randomized phase II design for biomarker threshold selec-
tion and independent evaluation. Chinese Clinical Oncology 2014:3(1). pii: 3489.
18. Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by
using fractional polynomials. Journal of the Royal Statistical Society: Series A (Statistics in Society) 1999; 162(1):71–94.
19. Schumacher M, Bastert G, Bojar H, Hübner K, Olschewski M, Sauerbrei W, Schmoor C, Beyerle C, Neumann RL,
Rauschecker HF. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in
node-positive breast cancer patients. German Breast Cancer Study Group. Journal of Clinical Oncology 1994;
12(10):2086–2093.
20. R Core Team. R: A Language and Environment for Statistical Computing, R.F.f.S. Computing (ed). : Vienna, Austria,
2015. Available at: https://www.R-project.org.
21. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective bio-
marker validation: SWOG S0819. Clinical Cancer Research 2012; 18(15):4004–4012.
Supporting information
Additional supporting information can be found in the online version of this article at the publisher’s
website.
A. V. SPENCER ET AL.
© 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 4909–4923
4923
